Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Still doing own due diligence. At risk of repeating info long ago posted, the competition, in part: the MDM2 inhibitors currently in trials as noted by review article J Med Chem 2015 58 1038-1052. (I would simply put up article, but my wife got it for me and she is a strong believer in not doing so- copyrighted, subscription. Sigh)

They(the compounds/drugs) seem to have different numbers assigned to them, and I have yet to go to each drug co. site to see what they say about the drugs, or to correlate with sclimmuno link to the clinical trials. ) Although I am interested i reading about the ecstasy studies too).

That of course is next obv step- again, perhaps also posted log since.


Roche RO5045337 First developed. Oral. 20 patients took for 6 mos. 12 SAE esp neutropenia and thrombocytopenia. Used in liposarcoma, a good target since 80% liposarcomas overamplify MDM2

Roche RO5503781 also oral. Similar toxicity. In 3 phase 1's according to article

Sanofi SAR405838 Developed at UMich Authors seem to favor it- but authors of review article are from UMich. In two phase 1's, no pub results One trial is single agent, another is with an MEK drug pimasertib again an oral agent

Amgen AMG 232 phase 1 started 2012 Oral.

Merck MK-8242 Oral


Next for me is to look more at each pharma info for these- apologies if you guys have already been over this in detail.

Novartis CGM097

Daiichi Sankyo DS-3032b